HCG Q1 FY27: Volume-led growth, better revenue mix, and a new Bengaluru bet

HealthCare Global Enterprises Limited (HCG) started FY27 with a quarter that was more about execution and mix than about headline realizations. For Q1 FY27, the company reported consolidated revenue of INR 6,951 million, up 13.4% year-on-year. Reported EBITDA stood at INR 1,223 million, while adjusted EBITDA was higher at INR 1,339 million, translating into an adjusted EBITDA margin of 19.4% versus 18.2% in Q1 FY26. Profit after tax came in at INR 138 million, up 190% year-on-year.

The operating engine was volume. Consolidated volumes (excluding fertility) rose 11% year-on-year to 78,914. ARPP increased only 2% to INR 85,943, and management attributed the modest realization growth to a mix effect. A more favourable payor mix helped, but it was partly offset by a lower contribution from high-value, low-margin therapies and shifts in specialty mix.

Mix improvement shows up in margins

A recurring theme in both the investor presentation and management commentary was “quality of revenue”. The payor mix chart in the presentation indicates a steady increase in cash share and a decline in government share over time (payor mix excludes fertility and international business).

In Q1 FY27, cash represented 41% of the mix, TPA and corporate was 25%, medical value travel was 3%, and government was 31%. Management also highlighted that non-institutional contribution improved from 67% in Q1 FY26 to 69% in Q1 FY27.

The management team also acknowledged that certain therapies were discontinued or rationalized because they were high value but low margin. On the earnings call, management quantified the top-line impact at about 1.5% in Q1, while noting that the step was margin accretive.

Notes: Adjusted EBITDA excludes North Bangalore loss of INR 70.2 million and an EPCG-related provision of INR 45.9 million in Q1 FY27, and excludes ESOP cost of INR 14.5 million and M&A-related costs of INR 25.6 million in Q1 FY26.

Cluster performance: East leads growth, West chooses margin over value

HCG’s revenue growth was broad-based, and management stated that 16 out of 25 centers (excluding North Bangalore) delivered their highest ever quarterly revenues. The cluster data in the presentation shows different growth drivers.

South delivered revenue of INR 2,765 million, contributing 40% of consolidated revenue, and grew around 16% year-on-year. Management highlighted balanced growth from volume and realization, and noted improvement in cash plus TPA mix at the Bengaluru Center of Excellence and the Vizag cluster. South also includes the newly commissioned North Bangalore facility.

West, which contributed 43% of revenue, reported INR 3,010 million and grew about 9% year-on-year. Maharashtra delivered stronger growth, but Gujarat saw moderated growth. Management explained on the call that institutional business in the West declined, consistent with the strategy of reducing low-margin scheme business and certain low-margin immunotherapies. This is one reason ARPP stayed broadly stable even as payor mix improved.

East was the fastest-growing cluster. Revenue rose about 22% year-on-year to INR 799 million on the back of 25% volume growth. ARPP declined 3% year-on-year to INR 64,983, which the company attributed to case-mix shifts and higher contribution from state-government schemes.

North Bangalore: early traction, still loss-making

The company’s most visible operational milestone this quarter was the launch of its North Bangalore hospital. Operations commenced in May 2026, and in Q1 FY27 the center contributed INR 67 million revenue. Management disclosed early operating traction: more than 550 new patient registrations and more than 300 admissions in the first quarter.

However, the new unit also dragged reported profitability. The consolidated P&L table shows North Bangalore losses of INR 70.2 million in Q1 FY27. Management stated that most costs have already been incurred, MR-LINAC commissioning was completed in July 2026, and the company believes it has reached peak EBITDA loss in this quarter. Management expects losses to reduce over the next few quarters as insurance empanelments get completed, clinician practices ramp up, and brand awareness builds.

On the call, management also indicated that while full utilization is difficult to predict, the facility could reach optimal utilization of about 60% to 65% in the third to fourth year of operations. The CFO added that the company expects monthly breakeven in FY27, given the initial response.

Expansion pipeline: 1,000 beds by FY30, led by brownfield

HCG’s growth plan is capacity-led but structured to lean on brownfield expansion. The bed addition slide in the presentation indicates a plan to add 188 beds in FY27, around 520 beds in FY28 and FY29, and around 230 beds in FY30, with about 60% of expansion coming from brownfield projects.

The company reported 2,734 operational beds as of 31 March 2026 and 2,855 operational beds in Q1 FY27, reflecting a net addition of 121 operational beds during the quarter. The presentation lists these as 56 beds at North Bangalore, 26 at Ranchi, 19 at Borivali, 8 at Nashik, 5 at Hubli, and 7 in Kenya.

Management also gave additional color on greenfield projects during the call. Two greenfield projects planned for FY28 and FY29 were stated to be in Whitefield (South cluster) and in Maharashtra (West cluster). Management suggested the South project is more likely to be operational towards the end of FY28.

Capital allocation: capex, debt and flexibility

HCG continues to position capital strength as a strategic advantage. Management stated that the rights issue strengthened the balance sheet and improved financial flexibility. The CFO disclosed on the call that rights issue proceeds were used for debt repayment of about INR 170 crore. The company also increased its shareholding in the Vizag hospital from 51% to 85% using about INR 150 crore, and used additional proceeds for general corporate purposes.

On capex, management disclosed that approximately INR 750 million was spent in Q1, split between growth capex and maintenance capex. For the full year, maintenance capex is expected to be around INR 100 crore.

What management is signaling from here

Guidance in this quarter was more directional than model-like, but there were a few explicit messages.

Management reiterated confidence in mid-teens growth across the existing network combined with the pipeline of brownfield and greenfield additions. On profitability, management stated a near-term target of 21% to 22% EBITDA margins over the next two years, and an aspiration to reach around 25% over four to five years. The largest lever highlighted was continued payor mix improvement.

The company also discussed cost optimization and productivity improvements. While no detailed line-item program was disclosed, management stated they see opportunities across cost line items, including manpower and other fixed costs, supported by automation and data analytics.

Marketing spend is another area where management offered quantification. On the call, management stated marketing expense is about 2.9% of sales in Q1 FY27 due to the North Bangalore launch, and that longer-term it is expected to normalize to around 2.5% to 2.6%.

Takeaways

Q1 FY27 reinforces that HCG’s strategy is shifting from portfolio clean-up to execution. The company has exited the fertility business, launched a key new hospital in North Bangalore, and is leaning into a brownfield-led bed expansion plan through FY30. Financially, the quarter shows that volume growth and mix improvement can expand margins even when ARPP growth is muted.

The near-term watchlist is clear from management commentary: reducing North Bangalore losses through ramp-up, sustaining the payor mix shift toward cash and TPA, and maintaining momentum in clusters where ARPP is pressured by case mix. If those levers stay on track, the company’s stated margin trajectory toward 21% to 22% over two years becomes easier to underwrite.